CURATIX, LLC
Total received in grants · trailing 12 months
$1.0M
$0for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $162.9B in tracked grants
1separate grants, trailing 12 months
CURATIX, LLC has received $1.0M across 1 federal grant of $1M or more on record.
Data as of July 24, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Health and Human Services | ENHANCING ANTIFUNGAL EFFICACY: LEVERAGING PCA PATHWAY INHIBITORS AS ANTIMICROBIAL ADJUVANTS - ABSTRACT FUNGAL INFECTIONS KILL MORE THAN 1.5 MILLION PEOPLE WORLDWIDE EACH YEAR. IN THE UNITED STATES, INVASIVE FUNGAL INFECTIONS (IFIS) ARE A SIGNIFICANT THREAT TO IMMUNOCOMPROMISED PATIENTS, LENGTHEN HOSPITAL STAYS AND INCREASE MORBIDITY. DEPENDING ON THE FORM OF IFI, THE MORTALITY RATES CAN BE AS HIGH AS 90%. THE CDC CURRENTLY CLASSIFIES MULTI-DRUG-RESISTANT CANDIDA AURIS AS AN URGENT THREAT, AND AZOLE-RESISTANT ASPERGILLUS SPECIES AS AN EMERGING THREAT. COMMON ANTIFUNGAL DRUGS (AFDS) INCLUDE ERGOSTEROL BIOSYNTHESIS INHIBITORS (EBIS: AZOLES, ALLYLAMINES, MORPHOLINES AND POLYENES) AND ECHINOCANDINS, ARE INCREASINGLY LESS EFFECTIVE DUE TO RISING RESISTANCE IN FUNGAL PATHOGENS, COUPLED WITH THEIR TOXICITY FOUND IN SOME DRUGS. THIS CREATES AN URGENT NEED FOR NOVEL ANTIFUNGAL STRATEGIES TO OVERCOME THESE LIMITATIONS AND IMPROVE PATIENT OUTCOMES. CURATIX PRESENTS A REVOLUTIONARY APPROACH TO ANTIFUNGAL THERAPY THROUGH ITS POTENTIATORS OF ANTIMICROBIAL SUSCEPTIBILITY (PAMS), A NOVEL CLASS OF ADJUVANT-LIKE MOLECULES. THOUGH PAMS EXHIBIT NO STANDALONE ANTIFUNGAL ACTIVITY, THEY DRAMATICALLY ENHANCE THE EFFICACY OF EXISTING FDA-APPROVED ANTIFUNGAL DRUGS WHEN USED IN COMBINATION. TARGETING THE PANTOTHENATE- COA PATHWAY (PCA PATHWAY), WHICH IS CRITICAL FOR COENZYME A (COA) AND ACETYL-COA (ACCOA) BIOSYNTHESIS, PAMS POTENTIATE THE ACTIVITY OF CONVENTIONAL DRUGS, SIGNIFICANTLY IMPROVING TREATMENT OUTCOMES. THIS COMBINATORIAL APPROACH NOT ONLY OVERCOMES DRUG RESISTANCE BUT ALSO ENABLES DOSE REDUCTION, THEREBY DECREASING DRUG TOXICITY AND COST, REPRESENTING A PIVOTAL ADVANCEMENT IN THE FIGHT AGAINST LIFE-THREATENING FUNGAL INFECTIONS. OUR LEAD COMPOUND, PAMS3.1, HAS SHOWN STRONG POTENTIAL IN PRECLINICAL STUDIES, ENHANCING THE EFFICACY OF ANTIFUNGALS AGAINST CANDIDA AURIS, CANDIDA ALBICANS, AND ASPERGILLUS FUMIGATUS, ALL OF WHICH ARE SIGNIFICANT CONCERNS IN CLINICAL SETTINGS. THE PROPOSED SBIR WILL EXPAND ON THESE FINDINGS BY EVALUATING 23 PAMS CANDIDATES AGAINST A BROAD SPECTRUM OF DRUG-SENSITIVE AND RESISTANT FUNGAL PATHOGENS. AIM 1 WILL BE TESTING OF BIOLOGICAL ACTIVITIES OF 23 PAMS CANDIDATES IN COMBINATION WITH ANTIFUNGAL DRUGS AGAINST DRUG-SENSITIVE AND DRUG-RESISTANT STRAINS OF FUNGAL PATHOGENS AND ASSESSING THEIR ABILITY TO POTENTIATE ANTIFUNGAL DRUGS. AIM 2 WILL FOCUS ON IN VITRO CYTOTOXICITY AND PHARMACOLOGICAL ANALYSIS OF SELECTED PAMS-DRUG COMBINATIONS, WHILE AIM 3 WILL ASSESS THE IN VIVO EFFICACY OF TWO LEADING COMBINATIONS IN MOUSE MODELS AND AGAINST CLINICAL ISOLATES. SUCCESSFUL COMPLETION OF THIS PROGRAM WILL PROVIDE CRITICAL DATA FOR ADVANCING A PAMS-ANTIFUNGAL COMBINATION TOWARDS CLINICAL TRIALS. THE COMMERCIALIZATION OF PAMS HAS THE POTENTIAL TO CAPTURE A SIGNIFICANT SHARE OF THE ANTIFUNGAL MARKET BY OFFERING A MORE EFFECTIVE AND SAFER TREATMENT OPTION FOR IFIS, ADDRESSING AN URGENT UNMET MEDICAL NEED AND PAVING THE WAY FOR BETTER PATIENT OUTCOMES WORLDWIDE. | $1,001,286 |